Adenomyosis Pathophysiology, Diagnostic Advances, and Therapeutic Options
other
OA: closed
public-domain-us
⚙
AI-generated summary
by gemini-2.5-flash-lite, 2026-06-13
ⓘ
This review covers adenomyosis pathophysiology, diagnostic advances in imaging, and current and emerging therapeutic options for symptom relief and uterine preservation.
⚙
AI-generated deep summary
by claude@2026-06, 2026-06-13
· read from full text
ⓘ
This paper reviews adenomyosis as a heterogeneous, nonmalignant uterine disorder marked by ectopic endometrium within the myometrium, producing abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. It describes proposed pathophysiologic mechanisms including sex-steroid imbalance, inflammation, fibrosis, neuroangiogenesis, and stem cell–mediated processes, and notes that recognition has broadened from older multiparous women to younger reproductive-aged patients due to advances in imaging. The paper emphasizes that diagnosis remains difficult because there is no consensus on histologic definitions, although improved imaging enhances noninvasive detection, and that medical options are largely extrapolated from endometriosis and leiomyoma evidence with variable efficacy. It also discusses interventional and surgical approaches such as uterine artery embolization, ablation techniques, and adenomyomectomy, while stating that recurrence and fertility outcomes are incompletely defined, highlighting the need for prospective trials and standardized diagnostic criteria. This paper is centrally about adenomyosis — it provides an overview of its pathophysiology, diagnostic advances, and therapeutic options.
Abstract
Adenomyosis is a heterogeneous, nonmalignant uterine disorder characterized by ectopic endometrium within the myometrium, leading to abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. Once considered a disease of multiparous women older than age 40 years, advances in imaging have expanded recognition to younger reproductive-aged patients. Pathogenesis involves sex steroid imbalance, inflammation, fibrosis, neuroangiogenesis, and stem cell-mediated mechanisms. Clinical presentation ranges from asymptomatic to severe pain and bleeding. Coexisting leiomyomas and endometriosis are common, compounding symptom severity and complicating management. Diagnosis remains challenging given a lack of consensus definitions for histologic diagnosis, although improved imaging techniques have enhanced noninvasive detection. Medical management is extrapolated largely from endometriosis and leiomyoma data, with progestins, levonorgestrel intrauterine systems, gonadotropin-releasing hormone analogs and antagonists, and emerging agents showing variable efficacy. Interventional and surgical options, including uterine artery embolization, radiofrequency ablation, high-intensity focused ultrasound, microwave ablation, and adenomyomectomy, offer symptom relief and uterine preservation, although recurrence and fertility outcomes remain incompletely defined. Adenomyosis imposes a significant burden across physical, psychologic, and socioeconomic domains. Advances in imaging, consensus regarding pathology, and novel therapies are reshaping management, underscoring the need for disease-specific prospective trials and standardized diagnostic criteria to optimize individualized, fertility-preserving care for this common, often misunderstood, condition.
Full text
2,104 characters
· extracted from
oa-doi-fallback
· click to expand
Adenomyosis is a heterogeneous, nonmalignant uterine disorder characterized by ectopic endometrium within the myometrium, leading to abnormal uterine bleeding, dysmenorrhea, chronic pelvic pain, and subfertility. Once considered a disease of multiparous women older than age 40 years, advances in imaging have expanded recognition to younger reproductive-aged patients. Pathogenesis involves sex steroid imbalance, inflammation, fibrosis, neuroangiogenesis, and stem cell–mediated mechanisms. Clinical presentation ranges from asymptomatic to severe pain and bleeding. Coexisting leiomyomas and endometriosis are common, compounding symptom severity and complicating management. Diagnosis remains challenging given a lack of consensus definitions for histologic diagnosis, although improved imaging techniques have enhanced noninvasive detection. Medical management is extrapolated largely from endometriosis and leiomyoma data, with progestins, levonorgestrel intrauterine systems, gonadotropin-releasing hormone analogs and antagonists, and emerging agents showing variable efficacy. Interventional and surgical options, including uterine artery embolization, radiofrequency ablation, high-intensity focused ultrasound, microwave ablation, and adenomyomectomy, offer symptom relief and uterine preservation, although recurrence and fertility outcomes remain incompletely defined. Adenomyosis imposes a significant burden across physical, psychologic, and socioeconomic domains. Advances in imaging, consensus regarding pathology, and novel therapies are reshaping management, underscoring the need for disease-specific prospective trials and standardized diagnostic criteria to optimize individualized, fertility-preserving care for this common, often misunderstood, condition.
Adenomyosis Pathophysiology, Diagnostic Advances, and Therapeutic Options
- Buy
- SDC
- PAP
Adenomyosis presents heterogeneously with bleeding, pain, and subfertility. Despite nonstandardized diagnostic criteria and limited evidence-based therapies, multiple medical and interventional options beyond hysterectomy now exist.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.
My notes (saved in your browser only)
⚙
Ask this paper
AI returns verbatim quotes from the full text
· source: oa-doi-fallback
ⓘ
Condition tags
endometriosisadenomyosischronic_pelvic_paindysmenorrhea
Citation neighborhood
(no data yet)
We don't have any in-corpus citations linked to this paper yet.
This is a recent paper (2026) — citers
typically take a year or two to land, and the OpenAlex reference
graph may still be filling in.
SciLite annotations
organisms 1
noordeloos 2009062
chemicals 3
steroid
progestin
levonorgestrel
Source provenance
- europepmc
- last seen: 2026-08-18T06:10:16.649438+00:00
- pubmed
- last seen: 2026-08-18T06:05:49.399059+00:00
- scilite
- last seen: 2026-08-02T09:40:10.667495+00:00
- unpaywall
- last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine